TabsDetailsBasic DetailsDate Posted: Friday, May 3, 2013Status: CompleteMedical Product: dabigatran, rivaroxaban, warfarinDescription: Modular program-based one-time assessment of the use of dabigatran, rivaroxaban, and warfarin in the Mini-Sentinel Distributed Database. Modular programs are adaptable standardized programs. Results were generated using Modular Program 1; click here for more information. Programs were executed in June 2012.If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer. Read More Deliverables (3)Mini-Sentinel Modular Program Report: Part-1-Dabigatran Rivaroxaban Warfarin Use 4Mini-Sentinel Modular Program Report: Part-2 Dabigatran Warfarin GIH-ICH2Mini-Sentinel_Modular Program Report: Part-3 Warfarin GIH ICH 2Additional InformationAdditional DetailsFDA Center: CDERTime Period: 2010 - 2011Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Mini-Sentinel Distributed Database (MSDD)
